PAG
SCNI

Private Advisor Group’s Scinai Immunotherapeutics SCNI Stock Holding History

Private Advisor Group’s Portfolio SCNI Stock Details SCNI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2
Closed -$5K – 3095
2020
Q2 		$5K Buy
+2
New +$3.22K ﹤0.01% 3265

Other funds holding SCNI

II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Private Advisor Group's SCNI Position: Q3 2020 in Review

Private Advisor Group sold out of Scinai Immunotherapeutics (SCNI) in Q3 2020, closing a stake of 2 shares — an estimated $5K sold.

Private Advisor Group first reported a position in SCNI in Q2 2020 and held it in 1 quarter. The position peaked at $5K in Q2 2020. 17 funds tracked by Wall St. Rank hold SCNI as of Q3 2020.

  • Private Advisor Group reported no remaining Scinai Immunotherapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 2 Scinai Immunotherapeutics shares in Q3 2020, an estimated $5K.
  • Private Advisor Group first reported a position in Scinai Immunotherapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Scinai Immunotherapeutics position peaked at $5K in Q2 2020.
  • 17 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.